Shilpa Medicare Ltd Stock Analysis

BSE: 530549 | NSE: SHILPAMED | Pharmaceuticals & Drugs | Small Cap

BSE Share Price 27-Sep-2023 18:03
353.70 0.60 (0.17%)

DeciZen - Make an Informed Decision on Shilpa Medicare

Overall Rating

1. Quality

2. Valuation

Somewhat Undervalued

3. Price Trend

Semi Strong

Shilpa Medicare Price Chart

P/E Ratio (CD):
Market Cap:
3,070.2 Cr.
52-wk low:
52-wk high:
Bole Toh?

1. Is Shilpa Medicare Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Shilpa Medicare Ltd is a good quality company.

2. Is Shilpa Medicare Ltd undervalued or overvalued?

The key valuation ratios of Shilpa Medicare Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone.

3. Is Shilpa Medicare Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Shilpa Medicare Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Shilpa Medicare:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Shilpa Medicare Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

ROCE % 17.1%11.8%15.4%10.8%8%6.8%9.6%5.2%3.3%-0%-
Value Creation Index 0.2-0.20.1-0.2-0.4-0.5-0.3-0.6-0.8-1.0-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 5716147167797897339089011,1461,0501,049
YoY Gr. Rt. %-7.4%16.7%8.8%1.2%-7%23.8%-0.8%27.1%-8.3%-
Adj EPS 11.19.414.4131210.717.710.95.9-4.9-3.7
YoY Gr. Rt. %--15.8%53.8%-10.1%-7.6%-10.6%65.6%-38.4%-46.3%-182.6%-
BVPS (₹) 53.970.982.9123.2133.1146.9163.1181.4209.9205.4205.8
Adj Net Profit 81.972.211110497.787.31458951-42.1-32
Cash Flow from Ops. 7068.812937.544.914712446.9105226-
Debt/CF from Ops.


CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 7%5.9%5%-8.3%
Adj EPS -191.2%-183.5%-164.9%-182.6%
Share Price 15.5% -2.7% -14.9% -1.1%

Key Financial Parameters

Performance Ratio Colour Code Guide

Return on Equity % 22.815.318.712.89.47.711.46.33.1-2.3-1.8
Op. Profit Mgn % 21.320.622.520.819.221.123.619.117.48.412.4
Net Profit Mgn % 14.211.61512.912.111.515.89.74.4-3.9-3.1
Debt to Equity
Working Cap Days 1351581581932372662302862803080
Cash Conv. Cycle 405659841161411261701641860

Recent Performance Summary

No data to display

Return on Equity is Poor

Sales growth has been subdued in last 3 years 4.97%

Sales growth is not so good in last 4 quarters at -9.39%

Latest Financials - Shilpa Medicare Ltd.

Standalone Consolidated
TTM EPS (₹) -5.2 -3.7
TTM Sales (₹ Cr.) 271 1,049
BVPS (₹.) 244.9 205.8
Reserves (₹ Cr.) 2,117 1,777
P/BV 1.44 1.72
PE 0.00 0.00
From the Market
52 Week Low / High (₹) 222.40 / 391.85
All Time Low / High (₹) 0.39 / 786.75
Market Cap (₹ Cr.) 3,070
Equity (₹ Cr.) 8.7
Face Value (₹) 1
Industry PE 42

Management X-Ray of Shilpa Medicare :

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.810.810.810.810.810.810.811.3812.9012.90
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Shilpa Medicare

Adj EPS (Rs.)
Sales (Cr.)
ROE (%)
ROCE (%)


Shilpa Medicare Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Shilpa Medicare on 27-Sep-2023 18:03 is : 353.7.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 27-Sep-2023 18:03 the market cap of Shilpa Medicare stood at ₹ 3,070.2.
The latest PE ratio of Shilpa Medicare as of 27-Sep-2023 18:03 is 0.00.
The latest PB ratio of Shilpa Medicare as of 27-Sep-2023 18:03 is 1.44
The 52-week high of Shilpa Medicare is ₹ 391.9 and the 52-week low is ₹ 222.4.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue / sales of Shilpa Medicare is ₹ 270.6 ( Cr.) .

About Shilpa Medicare Ltd

Shilpa Medicare, established in 1987, has carved a niche for itself in the exceedingly competitive and quality-conscious sphere of pharmaceuticals manufacturing. It produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.  

The company has earned its spurs as a successful and reliable partner within the pharmaceutical industry. Buyers within the country and from across the borders count on its fast track integrated process development and finely honed expertise of its skilled and experienced personnel. The company is already exporting to USA, Canada, Australia, Japan and European countries viz., Germany, Switzerland, Netherlands, Belgium, Spain, Greece, Cyprus, Italy, United Kingdom etc., South American countries like Mexico, Brazil, Columbia etc, African countries like Kenya, Nigeria and West Indies etc, Asian countries like Singapore, Taiwan, China, Malaysia, Thailand and closer to home to Iran, Egypt, Pakistan and Bangladesh.  Shilpa Medicare is synergizing strength through tie-ups for manufacturing products and co-marketing rights, for it believes in working together and sharing success.

Being proactive in approach, the company continually seeks out enquiry’s for development of new products drawing from the extensive knowledge-base of its qualified and experienced people as well as sophisticated facilities.

Product range of the company includes:

Oncology AP's

  • Anastrozole 
  • Bicalutamide 
  • Carboplatin 
  • Gemcitabine HCI
  •  Irinotecan HCl Trihydrate
  • Oxaliplatin 
  • Temozolomide 
  • Cisplatin 
  • 5-Fluoro
  • Bortezomib 
  • Capecitabine 
  • Decarbazine 
  • Docetaxel 
  • Gefitinib 
  • Hydroxy urea 
  • Imatinib Mesylate 
  • Lenalidomide 
  • Letrozole
  • Methotrexate 
  • Thalidomide 
  • Topotecan HCl
  • Zoledronic acid 

General APIs

  • Ambroxol HCl 
  • Ticlopidine HCl 
  • Buflomedil HCl 
  • Nifedipine 
  • Lamivudine 
  • Sildenafil Citrate 
  • Terfenadine 
  • Acebrophylline 
  • Phenylephrine HCl 
  • Ursodeoxycholic acid 


  •  Bendamustine Cladribine
  •  Decitabine Disodium Pamidronate
  •  Epirubicin Exemustane
  •  Fludarabine Phosphate  Idarubicine
  •  Paclitaxel  Pemetrexed
  •  Lomustine  Methotrexate
  •  Pamidronic acid  Tandutinib 


  • Chromium picolinate  Chromium polynicotinate   


  • Trans-4-amino cyclohexanol
  • 2-Amino-3,5-dibromobenzaldehyde
  • 1,3,5-Trimethoxy Benzene 
  • 1,3,5-Tribromo Benzene
  • 7-ethyl camptothecin 
  • 7-ethyl-10-hydroxy camptothecin

Awards & Achievements:

  • Karnataka State Govt. 'Best Enterpreneur Award'.
  • Govt. of India 'Best Enterpreneur Award'.
  • ‘Star Export House’ Status from Ministry of Commerce and Industry, Govt. of India
  • 'cGMP' Certificates from W.H.O. for 20 API's
  • 'Best Export Award' from Visvesvaraya Industrial Trade Centre, Bangalore, Govt. of Karnataka,  INDIA
  • 'Outstanding Industrial Award' from Indian Junior Chamber.
  • 'Registration with 'Russian Health Authority' for Ambroxol HCl
  • 'Certificate of Suitability' received from EDQM for Ambroxol HCl (R0-CEP 2004-201-Rev 00)
  • 'Certificate of Suitability' received from EDQM for Ticlopidine HCl (R0-CEP 2005-004-Rev 00)
  • 'Certificate of Suitability' received from EDQM for Carboplatin (R0-CEP 2006-212-Rev 00)
  • Patent application on Irinotecan HCl Trihydrate 'An improved process for the preparation of Irinotecan HCl Trihydrate' published as WO2006016203 on date 2006-02-16
  • Patent file for Gemcitabine HCl and Anastrozole manufacturing process.
  • Filed ASMF/EDMF of Gemcitabine HCl over 21 EU countries
  • Filed ASMF/EDMF of Irinotecan HCl Trihydrate HCl over 27 EU countries
  • Filed ASMF/EDMF of Oxaliplatin HCl over 11 EU countries
  • 'Best District Export Award' received from FKCCI, Bangalore on 16.06.2007
  • Korean FDA Approved for Gemcitabine HCl & Ambroxol HCl
  • COS received from EDQM for Buflomedil HCl (R0-CEP 2006-080-Rev.00)
  • COS received from EDQM for Oxaliplatin EP (R0-CEP 2006-201-Rev.00)
  • 'Best District Export Award' received from FKCCI, Bangalore on 20.06.2008.
  • COS received from EDQM for Gemcitabine HCl EP (R0-CEP 2006-222-Rev 00)
  • 2010 - Shilpa Medicare Limited was granted certificate of GMP Compliance of Manufacturer for Gemcitabine Hydrochloride
  • 2012 - Shilpa Medicare Ltd has been conferred First Prize of the National Energy Conservation Award-2012 in the Drugs & Pharmaceuticals Sector from Ministry of Power, New Delhi.
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now